157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Autor:	Oya, M.1 (AUTHOR), Armstrong, A.J.2 (AUTHOR), Thiery-Vuillemin, A.3 (AUTHOR), Shore, N.4 (AUTHOR), Procopio, G.5 (AUTHOR), Arslan, Ç.6 (AUTHOR), Mehra, N.7 (AUTHOR), Parnis, F.8 (AUTHOR), Brown, E.9 (AUTHOR), Constans Schlurmann, F.10 (AUTHOR), Joung, J.Y.11 (AUTHOR), Sugimoto, M.12 (AUTHOR), Sartor, O.13 (AUTHOR), Liu, Y-Z.14 (AUTHOR), Poehlein, C.H.15 (AUTHOR), Desai, C.16 (AUTHOR), Del Rosario, P.M.D.16 (AUTHOR), Clarke, N.17 (AUTHOR), Saad, F.18 (AUTHOR)
Zdroj:	Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1495-S1495. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu